EyePoint Pharmaceuticals, Inc. is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders. The company has developed DEXYCU, a proprietary product for the treatment of postoperative inflammation, and YUTIQ, a non-invasive, three-year treatment for chronic non-infectious uveitis affecting the posterior segment of the eye. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.